Ionis wins FDA approval to expand Tryngolza into severe hypertriglyceridemia, a far larger market than its rare FCS launch, with peak US sales seen topping $3B.

Ionis wins FDA approval to expand Tryngolza into severe hypertriglyceridemia, a far larger market than its rare FCS launch, with peak US sales seen topping $3B.

After 35 years engaged in the research and development of pharmaceutical products, Ionis began marketing its drugs for the first time in 2024. | Ionis has gained an FDA expansion…